The trial aims to enroll 700 participants, and will run 78 weeks (estimated readout 1H 2025)
No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: a pooled analysis of cardiovascular outcome trials
Thanks to advances like: Liposomal delivery: Encapsulates glutathione in phospholipid layers that protect it from digestive breakdown and enhance cellular uptake (NIH)
These ROS deplete hepatic glutathione and drive oxidative stress in liver cells
Design: Participants ( N =49, 1875 years, body mass index: 3040 kg m 2 ) were randomized to two of three treatments: liraglutide 1.8 mg, 3.0 mg, or placebo in a double-blind, incomplete crossover trial
One older study on Byetta (exenatide) showed minimal transfer, but there are no studies on semaglutide, tirzepatide, or liraglutide in breast milk, and no data on infant outcomes when exposed via breast milk